ACA
ORKA

Avoro Capital Advisors’s Oruka Therapeutics ORKA Stock Holding History

Avoro Capital Advisors’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,333,340
Closed -$40.4M – 39
2025
Q4 		$40.4M Hold
1,333,340
– – 0.4% 25
2025
Q3 		$25.6M Buy
+1,333,340
New +$19.8M 0.33% 24

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Avoro Capital Advisors's ORKA Position: Q1 2026 in Review

Avoro Capital Advisors sold out of Oruka Therapeutics (ORKA) in Q1 2026, closing a stake of 1,333,340 shares — an estimated $40.4M sold.

Avoro Capital Advisors first reported a position in ORKA in Q3 2025 and held it in 2 quarters. The position peaked at $40.4M in Q4 2025. 184 funds tracked by Wall St. Rank hold ORKA as of Q1 2026.

  • Avoro Capital Advisors reported no remaining Oruka Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Avoro Capital Advisors sold 1,333,340 Oruka Therapeutics shares in Q1 2026, an estimated $40.4M.
  • Avoro Capital Advisors first reported a position in Oruka Therapeutics in Q3 2025 and held it in 2 quarters.
  • Avoro Capital Advisors's Oruka Therapeutics position peaked at $40.4M in Q4 2025.
  • 184 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2026.

Based on Avoro Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.